Formulation of boronic acid compounds

a technology of boronic acid and compound, which is applied in the field of pharmaceutical compound formulation, can solve the problems of limited pharmaceutical utility of boronic acid compound, difficult to obtain alkylboronic acid in analytically pure form, and difficult to achieve the effect of enhancing stability, prolonging shelf life and convenient preparation

Inactive Publication Date: 2005-12-22
UNITED STATES OF AMERICA +1
View PDF18 Cites 38 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0011] The present invention provides stable, pharmaceutically acceptable compositions prepared from boronic acid compounds. The invention also provides methods for preparing such compositions. The invention provides the discovery that lyophilization of an aqueous mixture comprising a boronic acid compound and a compound having at least two hydroxyl groups produces a stable composition that readily releases the boronic acid compound upon dissolution in aqueous media.

Problems solved by technology

Unfortunately, alkylboronic acids are relatively difficult to obtain in analytically pure form.
Also, alkylboronic acids and their boroxines are often air-sensitive.
These difficulties limit the pharmaceutical utility of boronic acid compounds, complicating the characterization of pharmaceutical agents comprising boronic acid compounds and limiting their shelf-life.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Formulation of boronic acid compounds
  • Formulation of boronic acid compounds
  • Formulation of boronic acid compounds

Examples

Experimental program
Comparison scheme
Effect test

example 1

Preparation of a Lyophilized Formulation of N-(2-pyrazine)-carbonyl-L-phenylalanine-L-leucine Boronic Acid with D-mannitol

[0154] Approximately 40 mg of N-(2-pyrazine)carbonyl-L-phenylalanine-L-leucine boronic acid was weighed into a container, and 16 mL of tert-butanol was added. The container was closed and the suspension was warmed to approximately 45° C. for 5 minutes to complete dissolution of the compound. Water (24 mL) was added with stirring, followed by 0.4 g of mannitol, added as an excipient, 1% w / v. The mixture was stirred to complete dissolution and then cooled to ambient temperature. The solution was filtered through a 0.45 μm nylon membrane. One milliliter aliquots were placed in 5 mL serum bottles. Split rubber stoppers were partially inserted into the bottles, and the bottles were placed in a freeze dryer with a shelf temperature of −45° C. After approximately 1 hour, the vacuum was applied. The shelf temperature was allowed to rise gradually to −35° C. and maintain...

example 2

Production-Scale Preparation of a Lyophilized Formulation of N-(2-pyrazine)carbonyl-L-phenylalanine-L-leucine Boronic Acid with D-mannitol

[0157] In a clean compounding vessel, a solution of 97% tert-butanol / 3% Water for Injection was prepared by warming the required amount of tert-butanol to 35° C. and adding Water for Injection. Approximately 5% of the solution was reserved for use in rinsing. The solution was cooled to 15-30° C., and N-(2-pyrazine)carbonyl-L-phenylalanine-L-leucine boroxine was added with stirring. The container was rinsed with the reserved tert-butanol / water solution, and the rinses were added to the main vessel. The mixture was stirred until the boronic acid compound was completely dissolved. Mannitol was added, with residual mannitol being rinsed into the reaction vessel with fresh Water for Injection. Sufficient Water for Injection was added to reduce the total alcohol content to 40% v / v. The mixture was stirred until the mannitol was completely dissolved. Th...

example 3

Reconstitution of N-(2-pyrazine)carbonyl-L-phenylalanine-L-leucine Boronic Acid

[0165] The lyophilized formulation of N-(2-pyrazine)carbonyl-L-phenylalanine-L-leucine boronic acid with D-mannitol was prepared as described in Example 1. One sample was reconstituted with 2 mL of water. Dissolution was complete within 1-2 minutes of shaking. The entire solution was transferred to a volumetric flask, diluted, and analyzed by HPLC for content of N-(2-pyrazine)carbonyl-L-phenylalanine-L-leucine boronic acid. The total drug content was 1.09 mg. A second sample was reconstituted with 1 mL of propylene glycol:EtOH:H2O, 40:10:50. Dissolution was complete with 1 minute of shaking. The total drug content was 1.11 mg.

[0166] The lyophilized formulation was also reconstituted with 0.9% w / v saline. The lyophilized material dissolved readily at concentrations up to 6 mg / mL. By contrast, solid N-(2-pyrazine)carbonyl-L-phenylalanine-L-leucine boronic acid was not soluble in 0.9% w / v saline at a conce...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
temperatureaaaaaaaaaa
temperatureaaaaaaaaaa
molar ratioaaaaaaaaaa
Login to view more

Abstract

The invention relates to the formulation of pharmaceutical compounds. More particularly, the invention provides stable, pharmaceutically acceptable compositions prepared from boronic acid compounds and methods for preparing the compositions. The invention also provides novel boronate ester compounds. The invention further provides boronic acid anhydride compounds useful in the methods of the invention.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS [0001] This application claims priority from U.S. Provisional Patent Application Ser. No. 60 / 264,160.GOVERNMENT FUNDING [0002] Work described herein was performed under Collaborative Research and Development Agreement (CRADA) Number 0676. The United States Government has certain rights in the invention.BACKGROUND OF THE INVENTION [0003] 1. Field of the Invention [0004] This invention relates to the formulation of pharmaceutical compounds. More particularly, the invention relates to stable, pharmaceutically acceptable compositions prepared from boronic acid compounds. The invention also relates to methods for preparing such compositions. [0005] 2. Summary of the Related Art [0006] Boronic acid and ester compounds display a variety of pharmaceutically useful biological activities. Shenvi et al., U.S. Pat. No. 4,499,082 (1985), discloses that peptide boronic acids are inhibitors of certain proteolytic enzymes. Kettner and Shenvi, U.S. Pat. No. 5,...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/69A61K38/00A61K9/19A61K38/14A61P29/00A61P31/18A61P35/00A61P37/02A61P43/00C07F5/02C07F5/04C07F5/05C07H9/00C07K5/06C07K5/062C07K5/065C07K5/078C07K5/08C07K5/083C07K5/097C07K5/117C07K7/02C07K9/00
CPCA61K38/00C07F5/025C07K7/02C07K5/06191C07K5/0827C07F5/04A61P29/00A61P31/18A61P35/00A61P37/02A61P43/00
Inventor PLAMONDON, LOUISGRENIER, LOUISADAMS, JULIANGUPTA, SHANKER LAL
Owner UNITED STATES OF AMERICA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap